Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01876511 · ClinicalTrials.gov registry record · Phase 2
Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C)
A Phase 2 study of MSI Positive Colorectal Cancer and MSI Negative Colorectal Cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 113
- Enrollment target
- 7
- Study locations
NCT01876511 is a Phase 2 study of MSI Positive Colorectal Cancer and MSI Negative Colorectal Cancer that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 113 participants. The trial reports 7 study locations across 5 states.
The verdict
NCT01876511, a Phase 2 study of MSI Positive Colorectal Cancer and MSI Negative Colorectal Cancer, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 113 participants
- Enrollment target
- 7
- Study locations
Study Summary
This study will be looking at whether MK-3475 (an antibody that blocks negative signals to T cells) is effective (anti-tumor activity) and safe in three different patient populations. These include: 1. patients with MSI positive colon cancer, 2. patients with MSI negative colon cancer and 3. patients with other MSI positive cancers.
Conditions Studied
Interventions
- DRUG MK-3475
Study Locations (7)
Maryland
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore
- Investigator Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, NIH - Bethesda
Pennsylvania
- University of Pennsylvania, Abramson Cancer Center - Philadelphia
- University of Pittsburgh Cancer Institute - Pittsburgh
California
- Stanford University - Stanford
Ohio
- Ohio State University - Columbus
Oregon
- Providence Portland Medical Center - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2013-09 |
| Est. Completion | 2019-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01876511
The ClinicalTrials.gov registry entry for NCT01876511 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 113 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with MSI Positive Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which MK-3475 is the first listed.
NCT01876511 reports 7 study locations spanning 5 distinct geographic areas - top geographies include Maryland, Pennsylvania, California.
Frequently Asked Questions
What is clinical trial NCT01876511 about?
NCT01876511 is a clinical study titled "Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C)". This study will be looking at whether MK-3475 (an antibody that blocks negative signals to T cells) is effective (anti-tumor activity) and safe in three different patient populations. These include: 1. patients with MSI positive colon cancer, 2. patients with MSI negative colon cancer and 3. patient...
What is the current status of trial NCT01876511?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 113 participants. The study started on 2013-09. Estimated completion is 2019-08.
What conditions does trial NCT01876511 study?
This clinical trial studies the following conditions: MSI Positive Colorectal Cancer, MSI Negative Colorectal Cancer, MSI Positive Non-Colorectal Cancers.
What interventions are being tested in trial NCT01876511?
The interventions under investigation include: MK-3475 (DRUG).
Who is sponsoring clinical trial NCT01876511?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01876511 being conducted?
This trial has 7 study locations across California, Maryland, Ohio, Oregon, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
MSI Positive Colorectal Cancer
All registered trials for this condition
MSI Negative Colorectal Cancer
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.